COVID-19: Do DNA / RNA vaccines integrate into the genome?
Keywords:Vaccine; COVID-19; Coronavirus; RNA; DNA.
The new coronavirus pandemic brought the need for researchers to work tirelessly in the search for therapies or vaccines that would allow control of the spread of the virus around the world. Fortunately there are two RNA vaccines against COVID-19 that have finished clinical tests and are approved in some countries. They are the first third generation vaccines approved in history and in time record. But still have some concerns about safety of DNA/RNA vaccines. Here we bring a discussion about safety of DNA/RNA: can these vaccines be integrated to the genome? In fact, DNA vaccines have an infinite chance to integrate in the cell's genome, but this infinite chance is equal zero when used with RNA-based vaccines. The vaccines based on nucleic acid (DNA and RNA) have been corresponding in advantages, becoming promising alternatives to guarantee the immunization of the new coronavirus.
Baric, R. S. (2020). Emergence of a Highly Fit SARS-CoV-2 Variant. New England Journal of Medicine. 10.1056/NEJMcibr2032888.
Campos, E. V. R., Pereira, A. E. S., de Oliveira, J. L., et al. (2020). How can nanotechnology help to combat COVID-19? Opportunities and urgent need. Journal of Nanobiotechnology. 18(1):1–23. https://doi.org/10.1186/s12951-020-00685-4.
Fuller, D. H., & Berglund, P. (2020). Amplifying RNA vaccine development. New England Journal of Medicine. 382(25):2469-2471.10.1056 / NEJMcibr2009737.
Koirala, A., Jin Joo, Y., Khatami, A., Chiu, C., & Britton, P. N. (2020). Vaccines for COVID-19: the current state of play. Pediatric Respiratory Reviews. 10.1016 / j.prrv.2020.06.010.
Kutzler, M. A., & Weiner, D. B. (2008). DNA vaccines: ready for prime time? Nature Reviews Genetics. 2008; (9)10:776–788. 10.1038/nrg2432.
Ledford, H. (2020). Moderna COVID vaccine becomes second to get US authorization: Two RNA vaccines will be useful as US infections surge, but the speedy authorizations complicate clinical trials. Nature News. <https://www.nature.com/articles/d41586-020-03593-7>.
Liu, M. A. (2019). A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines. 2019; 7(2), 37. https://doi.org/10.3390/vaccines7020037.
Mahase, E. (2020). Covid-19: What do we know about the late stage vaccine candidates? British Medical Journal Publishing Group. 371:m4576. https://doi.org/10.1136/bmj.m4576.
Mahase, E. (2020b). Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week. British Medical Journal Publishing Group.
Mufamadi, M. S. (2020). Nanotechnology shows promise for next-generation vaccines in the fight against COVID-19. Material Matters. 45 (12): 981-982. 10.1557 / mrs.2020.307.
Naik, R., & Peden, K. (2020). Regulatory Considerations on the Development of mRNA Vaccines. In: Current Topics in Microbiology and Immunology. Springer, Berlim, Heidelberg. https://doi.org/10.1007/82_2020_220.
Pacheco, T. J. A., Silva, F. M., Souza, D. G., Silva, V. C. M., & Faria, R. S. (2020a). Coronavirus disease 2019 (COVID-19): Updated evidence of comparative overview, diagnosis and treatments. Revista Cereus. 12(3):228–243. 10.18605/2175-7275/cereus.v12n3p228-243.
Pacheco, T. J. A., Silva, V. C. M., & Souza, D. G. (2020b). Nano COVID-19 Vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history – Review. Research, Society and Development. 2020b; 9(12), e20191211123. 10.33448/rsd-v9i12.11123.
Ulmer, J. B., Mason, P. W., Geall, A., Mandl, C. W. (2012). RNA-based vaccines. Vaccine. 30(30), 4414–4418. 10.1016 / j.vaccine.2012.04.060.
Who. World Health Organization. (2020). Draft landscape of COVID-19 candidate vaccines. <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>.
Wu, D., Koganti, R., Lambe, U. P., Yadavalli, T., Nandi, S. S., & Shukla, D. (2020). Vaccines and Therapies in Development for SARS-CoV-2 Infections. J. Clin. Med. 2020, 9(6), 1885. https://doi.org/10.3390/jcm9061885.
Wang, Z., Troilo, P. J., Wang, X., Griffiths, I. I. T. G., Pacchione, S. J., Barnum, A. B., et al. (2004). Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 11: 711–721. https://doi.org/10.1038/sj.gt.3302213.
Ye, T., Zhong. Z., García-Sastre, A., Schotsaert, M., & Geest, B. G. D. (2020). Current Status of COVID-19 (Pre) Clinical Vaccine Development. Angew.Chem. Int. Ed. 59, 18885–18897. International Edition: doi.org/10.1002/anie.202008319. German Edition: doi.org/10.1002/ange.202008319.
How to Cite
Copyright (c) 2021 Thyago José Arruda Pacheco; Victor Carlos Mello da Silva; Danielle Galdino de Souza; Maria Blandina Santos Borges; Sebastião Andrade e Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.